NPRA Registration and Import Pathway for Injectable Vitamin Products in Malaysia

In short: in our reading of NPRA's Drug Registration Guidance Document (DRGD), an injectable vitamin or nutrient product may be imported, sold or supplied in Malaysia only after the Drug Control Authority (DCA) has registered it. The applicant is a locally incorporated Product Registration Holder; a product made abroad needs a Certificate of Pharmaceutical Product (or one of the alternatives the DRGD lists) and GMP evidence for every manufacturer; and NPRA's stated full-evaluation targets run from 210 to 245 working days. Until registration, a product cannot lawfully be sold or advertised.

This guide is for licensed importers, distributors and healthcare facilities in Malaysia that may be offered injectable vitamin or nutrient products made abroad, and for manufacturers considering the market. It summarises, in outline, how registration with the Drug Control Authority works, what a Malaysian applicant must hold and which licences an importer needs.

It is information for licensed businesses and healthcare professionals, not legal advice. It summarises NPRA's public documents as read in November 2026: the Drug Registration Guidance Document (DRGD), Third Edition, 12th Revision, July 2026, with its appendices, and the Foreign GMP Inspection Guidance Document, 11th Edition, June 2026. NPRA may amend either document, and the current official text applies.

The rule: registration comes first

Regulation 7(1) of the Control of Drugs and Cosmetics Regulations 1984 (CDCR) provides that, except as otherwise provided, no person shall manufacture, sell, supply, import, possess or administer any product unless the product is a registered product and the person holds the appropriate licence issued under the Regulations. The Drug Control Authority decides on registration, with the National Pharmaceutical Regulatory Agency (NPRA) acting as its secretariat. A registered product receives a registration number beginning with the letters MAL, assigned through NPRA's QUEST system, which is specific to the product as registered, including its manufacturer and registration holder, and may not be used for any other product.

Registration is not permanent. The DRGD states that it is valid for five years or the period shown in NPRA's database, that a renewal application is made within six months before expiry, and that a product whose registration has expired is deemed unregistered.

Who can apply: the Product Registration Holder

The DRGD calls the applicant the Product Registration Holder (PRH). The PRH must be a locally incorporated company, corporate or legal entity with a permanent address, registered with the Companies Commission of Malaysia (SSM) with a business scope related to health or pharmaceutical products. If the PRH is not the product owner, the owner must authorise it in writing to hold the registration and to answer for all matters of quality, safety and efficacy, including keeping product information up to date. A foreign manufacturer therefore works through a Malaysian company.

The PRH takes on continuing duties:

• All dealings with NPRA run through the PRH's appointed persons on the online QUEST system, and NPRA corresponds only with the existing PRH, not with the product owner or a law firm.
• A change to any submitted document or particular is notified to NPRA within 14 days (CDCR regulation 8(5)); knowingly giving false or misleading information is an offence (regulation 8(9)); NPRA is told at once if the company ceases to be the holder.
• The PRH is responsible after registration for quality, safety and efficacy information, for reporting adverse reactions and for product recalls.

Which category does an injectable fall into?

The DRGD's main body lists the registration categories: new drug products, biologics, generics, health supplements, natural products and veterinary products. Its health supplement appendix (Appendix 6) defines a health supplement as a product in small unit dosage forms such as capsules, tablets, powder and liquids, states that it shall not include sterile preparations such as injectables, limits the route to oral and lists “any injectable and sterile preparation” among its exclusions. An injectable vitamin or nutrient formulation therefore cannot be registered as a health supplement. The category that does apply is NPRA's decision: the DRGD allows an applicant who cannot determine the category to submit a Classification Form. We have not seen an NPRA statement that names the category for injectable vitamin products, so we regard the point as unconfirmed, and an importer should ask NPRA before a dossier is planned. The category matters because it sets the evaluation route and the stated timeline.

The dossier and certificates for imported products

Applications are submitted online through QUEST. A full evaluation follows the ASEAN Common Technical Dossier (ACTD) or ICH structure: Part I administrative data and product information, Part II quality, Part III nonclinical and Part IV clinical. For a product made outside Malaysia, Appendix 29 (Certificate) and the main body add the following documents.

GMP evidence from a foreign manufacturer

NPRA's guidance on foreign GMP inspection (11th edition, June 2026) states that one requirement for registering an imported medicinal product is acceptable documentary evidence, issued by a regulatory authority, that the manufacturer follows GMP. NPRA assesses against the current PIC/S Guide to GMP, and Malaysia has been a PIC/S member since 2002. Since 1 July 2018 the guidance accepts:

• for a site within the jurisdiction of a PIC/S participating authority, GMP evidence from that authority;
• for a site in an ASEAN country, evidence from an authority listed under the ASEAN mutual recognition arrangement on GMP inspection;
• for any other site, evidence issued by a PIC/S participating authority or by an authority with a cooperation agreement with PIC/S.

The evidence must still be current, carry the correct manufacturer name and site address, and either specify the dosage form class or confirm that the facility making that form was covered. Where acceptable evidence is missing or insufficient, NPRA conducts an on-site inspection, and submitting evidence does not mean that NPRA will not inspect.

Timelines, validity and the facilitated pathway

Section 10.3 of the DRGD sets the evaluation timelines, counted from confirmation of payment of the processing and analysis fee. For full evaluation they are 245 working days for new chemical entity drug products and biologics, and 210 working days for hybrid new drug products and for scheduled and non-scheduled generics. The abridged categories carry shorter targets of 100 to 136 working days. The DRGD adds that the Drug Evaluation Committee sets the final timeline for a product needing an extensive review. These are NPRA's stated targets rather than commitments; the real time depends on how complete the dossier is, the questions raised and any inspection.

Appendix 14 also describes a facilitated registration pathway that relies on prior assessment by listed reference authorities, and NPRA announced a one-year pilot of a Facilitated Registration Pathway from 2 May 2026 with a processing target of 60 working days. Both depend on an existing approval by a designated reference authority; they do not apply to IVIXIR.

Licences for importers and wholesalers

Registration of the product is separate from the licences of the businesses that handle it. Under regulation 12 of the CDCR, a company that wants to manufacture, import or act as a wholesaler of registered products needs a valid manufacturer's licence, import licence or wholesaler's licence (DRGD section 16 and Appendix 28). An import licence authorises the licensee to import registered products and to supply them onward from the premises named in the licence. Where scheduled poison products are involved, the application also needs a Type A poison licence for wholesalers. Each licence is valid for one year or until 31 December of the same year. Compliance with Good Distribution Practice (GDP) is a prerequisite for an import or wholesaler's licence.

Before registration

The Ministry of Health's Pharmaceutical Services Programme states in its public FAQ that medicines without a MAL registration number are considered unregistered products, are not allowed to be sold or advertised in Malaysia, and that the Medicine Advertisements Board will not approve an advertisement for an unregistered product. The rules on advertising are the subject of our guide to Act 290 and the Medicine Advertisements Board. For a partner, the practical reading is that the registration comes first and that commercial discussion follows it.

Checklist for importers and distributors

For a company that may become the PRH

• A company incorporated in Malaysia, registered with the Companies Commission with a business scope that covers health or pharmaceutical products, and a permanent address.
• A written letter of authorisation from the product owner, naming who files, who holds the registration and who answers for the product after registration.
• Regulatory affairs staff able to prepare an ACTD dossier, use QUEST and answer NPRA's queries, and a Classification Form if the category is unclear.
• The manufacturer's CPP, or an accepted alternative, and GMP evidence for every site, checked against the acceptance rules above before filing.
• An import licence and, if it also distributes, a wholesaler's licence, with a GDP-compliant store and cold chain where the label requires one.

For distributors and healthcare facilities

• Establish who holds, or will hold, the registration and whether its registration number can be verified before any commercial step.
• Do not stock, list or promote an unregistered product, and do not repeat a manufacturer's claims in your own materials.
• Regard an offer to “arrange import” of an unregistered injectable as a red flag.

EFBA's position and partnership search

EFBA manufactures the IVIXIR range of professional IV vitamin and nutrient formulations. IVIXIR products do not currently hold an NPRA or DCA registration and have no MAL number, and the registration route above is the only route we consider. EFBA is looking for a company in Malaysia able to act as Product Registration Holder and a licensed importer; the technical documents a dossier needs can be discussed with a qualified partner through the contact form. IVIXIR products are supplied in Malaysia only after NPRA registration through a licensed importer; samples are not offered via this website. If you represent a licensed importer or distributor, the distributor partnership page explains how a conversation starts.